These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 21222333)

  • 41. Osteoporosis: a focus on treatment.
    Shiflett S; Cooke CE
    Md Med J; 1997 Jul; 46(6):303-7. PubMed ID: 9579203
    [No Abstract]   [Full Text] [Related]  

  • 42. Femoral strength in osteoporotic women treated with teriparatide or alendronate.
    Keaveny TM; McClung MR; Wan X; Kopperdahl DL; Mitlak BH; Krohn K
    Bone; 2012 Jan; 50(1):165-70. PubMed ID: 22015818
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Corticosteroids: no drug prevention of fractures needed.
    Prescrire Int; 2009 Aug; 18(102):175. PubMed ID: 19746563
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Bone density measurements after alendronate therapy?].
    Schoppmeyer M
    Med Monatsschr Pharm; 2015 May; 38(5):196-7; discussion 197. PubMed ID: 26364412
    [No Abstract]   [Full Text] [Related]  

  • 46. Randomized controlled clinical trials and meta-analyses.
    Pfeifer M
    Arch Osteoporos; 2015; 10():42. PubMed ID: 26602100
    [No Abstract]   [Full Text] [Related]  

  • 47. Bone health in cystic fibrosis: use of oral bisphosphonates.
    Le Henaff C; Velard F; Jacquot J
    Lancet Respir Med; 2013 Jul; 1(5):349-50. PubMed ID: 24429188
    [No Abstract]   [Full Text] [Related]  

  • 48. Low creatinine clearance, glucocorticoid treatment, rheumatoid arthritis--different etiologies for low D-hormone syndrome and its associated increased risk for falls.
    Dukas LC; Schacht E
    J Rheumatol Suppl; 2005 Sep; 76():44-6. PubMed ID: 16142851
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alendronate may enhance implant osseointegration, study finds.
    J Am Dent Assoc; 2008 Jun; 139(6):679-80. PubMed ID: 18519989
    [No Abstract]   [Full Text] [Related]  

  • 50. [Alendronate and mouth ulcers: careful interrogation of the patient to start with].
    Schmutz JL; Barbaud A; Trechot P
    Ann Dermatol Venereol; 2005 Nov; 132(11 Pt 1):930. PubMed ID: 16327732
    [No Abstract]   [Full Text] [Related]  

  • 51. Case of alfacalcidol-induced hypercalcemia presenting as bipolar disorder.
    Tamiya H; Okamura T; Iwashiro N; Ishiki K; Yamasue H; Kasai K
    Psychiatry Clin Neurosci; 2011 Aug; 65(5):536-7. PubMed ID: 21851468
    [No Abstract]   [Full Text] [Related]  

  • 52. The Large Pharmaceutical Company Perspective.
    Rosenblatt M
    N Engl J Med; 2017 Jan; 376(1):52-60. PubMed ID: 28052221
    [No Abstract]   [Full Text] [Related]  

  • 53. Potential of alfacalcidol for reducing increased risk of falls and fractures.
    Ringe JD; Schacht E
    Rheumatol Int; 2009 Aug; 29(10):1177-85. PubMed ID: 19159932
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures.
    Schacht E; Richy F; Reginster JY
    J Musculoskelet Neuronal Interact; 2005; 5(3):273-84. PubMed ID: 16172518
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Osteoporosis. Improving bone and muscle performance].
    MMW Fortschr Med; 2010 Dec; 152(48):36. PubMed ID: 21222333
    [No Abstract]   [Full Text] [Related]  

  • 56. Potency of a combined alfacalcidol-alendronate therapy to reduce the risk of falls and fractures in elderly patients with glucocorticoid-induced osteoporosis.
    Ringe JD; Schacht E; Dukas L; Mazor Z
    Arzneimittelforschung; 2011; 61(2):104-11. PubMed ID: 21428245
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk reduction of falls and fractures, reduction of back pain and safety in elderly high risk patients receiving combined therapy with alfacalcidol and alendronate: a prospective study.
    Schacht E; Ringe JD
    Arzneimittelforschung; 2011; 61(1):40-54. PubMed ID: 21355445
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.